The Center for Biosimilars® recaps the top news for the week of October 1, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 1.
Number 5: The FDA announced this week a revised draft guidance that it says will help ensure that citizen petitions cannot be used by brand-name drug makers to delay the market entry of generics or biosimilars of branded products.
Number 4: A recent study randomized and dosed 589 patients with breast cancer with either Apotex’s pegfilgrastim biosimilar, the European Union-licensed reference pegfilgrastim, or the United States-licensed reference pegfilgrastim, and found that the biosimilar demonstrated similarity to both reference products.
Number 3: The FDA has released a draft guidance document relating to potential fines that may be incurred if submitters of data and trial information on clincialtrials.gov either do not report clinical trial results, or misreport findings.
Number 2: The Association for Accessible Medicines and the Biosimilars Council, a division of AAM, have submitted comments to the FDA in reference to its Biosimilar Action Plan.
Number 1: Pfizer has indicated that its filgrastim biosimilar, Nivestym, will be priced at a wholesale acquisition cost of 350 dollars and 40 cents per 480 microgram pre-filled syringe, which accounts for a 30.3% discount to that of the reference product, Neupogen.
Finally, last week, our e-newsletter asked whether direct-to-consumer advertising should include drugs’ list prices.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.